Patients 172,350+ 277,350+ 890,100+ 99,600+ 1,451,100+

Studies 1,750+ 1,600+ 1,500+ 200+ 5,100+Investigator

Sites 6,300+ 33,900+ 91,750+ 6,600+ 139,200+

Study counts include historical CLS+ LabCorp Clinical Trials data. Investigator site and patient counts include only CLS data. Therapeutic study counts are CLS only.

Source: Internal metrics 2011-2015

Numberof studies

2011-2015

48 of the 50best-selling drugs in 2015 were

developed in partnership with

Covance Central Laboratory Services.

Unparalleled therapeutic experience over the

past 5 years. Over 5,100 studies, more

than 2x as many as any other central lab.

Unique insights in all therapeutic areas...

...and at every step of the process.

PHASE I

IND NDAPHASE II TOTAL

PHASE III PHASE IV

CentralNervous System

820

Oncology

1,266

Endocrine/Metabolic

692

ImmuneSystem

882

InfectiousDiseases

525

YOUR JOURNEY FROMIND TO NDA... AND BEYOND

per day by reducing the risk of delaysto your trial completion milestones

Our on-time delivery can save you

$600,000+

Proven results at every stage of the trial

OUR SOLUTIONS TO MEET YOUR STUDY MILESTONES

START UP

EXECUTION

DELIVERY

BETTER DECISIONS, FASTEROur global automation strategy delivers consistent results.

SAVING SAMPLES MEANS SAVING MONEY Data reconciliation speeds data submissions. Covance delivered 99.4% of data packages on time in 2015.

Reportabletest yields

98.3%

Sample receiptwithin stability

99.2%

You can count on our ability to deliver: Over 2,000,000 shipments to and from over 85 countries each year.

The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440

Europe / Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588

© Copyright 2016 Covance Inc. INFCLS005-1116

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and itssubsidiaries around the world.

Source: LifeScience StrategyGroup survey, 2016

INVESTIGATORS PREFER COVANCE BY 3XMeet your enrollment milestones faster withengaged investigators and on-time kit delivery.